RespiDART 2022: Frontiers in Drug Development against Respiratory Viruses

RespiDART 2022：抗呼吸道病毒药物开发的前沿

• 批准号: 10609297
• 负责人: Asuncion Mejias
• 金额: $ 0.65万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-12-01 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10609297
• 关键词: 2019-nCoV; Accreditation; Address; Adult; Antiviral Agents; Antiviral Therapy; Area; Biological Assay; Biology; COVID-19; COVID-19 pandemic; Chemistry; Childhood; Clinical; Clinical Research; Communities; Coronavirus; Data; Developing Countries; Development; Diagnosis; Drug resistance; Education; Educational workshop; Elderly; Environment; Enzymatic Biochemistry; Epidemiology; Evolution; Future; Goals; HIV; Health; Health Personnel; Hepatitis B; Hepatitis C; Human; Immunocompromised Host; Immunology; Infant; International; Knowledge; Location; Long COVID; Measures; Medical; Metapneumovirus; Methods; Mexican; Mexico; Oral; Participant; Pharmacology; Population; Postdoctoral Fellow; Program Effectiveness; Public Health; Resistance; Respiratory Disease; SARS-CoV-2 variant; Safety; Scholarship; Scientist; Series; Services; Socialization; Special Population; Surveys; Therapeutic; Training; Travel; Vaccination; Vaccines; Viral; Virus; Virus Diseases; Virus Replication; Vulnerable Populations; animal model development; barrier to care; co-infection; coronavirus pandemic; cross disciplinary program; design; drug development; drug discovery; effectiveness evaluation; frontier; global health; graduate student; influenzavirus; lectures; meetings; novel; novel therapeutics; pandemic disease; parainfluenza virus; peer; posters; programs; research and development; research clinical testing; respiratory virus; screening; small molecule; sobriety; symposium; therapeutic development; therapy development; tool; vaccine development; virtual; virus host interaction

Abstract/ Project Summary Since 1995, the DART conference series have focused on the latest developments in antiviral therapy against viruses such as HIV, hepatitis B and hepatitis C. Just as viruses are ever evolving, the DART series strives to adapt itself to emerging challenges facing today’s global community. Respiratory viruses such as RSV and influenza virus have longed threatened human health, especially in vulnerable populations such as infants, the elderly, and the immunocompromised. The recent coronavirus pandemic has shaken the world to its core and has served as a sobering reminder of the importance of continued research and development in this arena. By bringing together world leaders and key opinion holders, RespiDART 2022 will tackle challenges in drug discovery/development and vaccines against respiratory viruses. The specific aims are: 1. To provide an interactive workshop setting where clinicians, scientists and health care workers can share and discuss the latest medical and scientific developments in the field of therapeutics development against respiratory viruses; 2. Develop a cross-disciplinary program that facilitates the neutral and balanced exchange of scientific knowledge in the areas of biology, chemistry, pharmacology, clinical research and public health as related to topics such as epidemiology and barriers to treatment, vaccine development, and recent clinical advances of small molecules; 3. Enhance the training of young scientists and provide increased opportunities for underrepresented scientists and health care workers through attendee scholarships in a CME accredited setting. The educational objectives are: 1. Epidemiology, screening, and diagnosis of respiratory viruses with a special focus on SARS-CoV-2. 2. Drug discovery and development. 3. Clinical evaluation of novel therapeutics in development against respiratory viruses such as SARS-CoV-2. influenza virus, RSV, parainfluenza virus, and metapneumovirus. 4. Long COVID-19. 5. Respiratory virus enzymology, host-virus interactions and virus replication. 6. Immunology and vaccine development. 7. Impact of SARS-CoV-2 variant emergence on therapeutics, vaccines and epidemiology. 8. Novel assay and animal model development. 9. Drug resistance, vaccine resistance, and viral evolution. 10. SARS-CoV-2 and other viral infections and respiratory diseases in adults and pediatric populations, including SARS-CoV-2/viral coinfections. Design & Methods: RespiDART 2022 will take place in Los Cabos, Mexico over a two-day period, at a location that is easily accessed by both national and international delegates. Mexican doctors (including those servicing the local population) as well as numerous scientists from underdeveloped countries will be invited to attend. The program will include lectures, oral abstract presentations, discussion panels and a poster session. Virtual participation option will be set up in case the ongoing pandemic makes it unsafe to travel to the conference. We believe that RespiDART 2022 is a much needed and timely platform for the discussion of the latest developments in this fast-evolving area of global health.

摘要/项目摘要 自 1995 年以来，DART 系列会议一直关注抗病毒治疗的最新进展 病毒，如 HIV、乙型肝炎和丙型肝炎。正如病毒不断进化一样，DART 系列致力于 适应当今全球社会面临的新挑战，如呼吸道合胞病毒和呼吸道病毒。 流感病毒长期以来威胁着人类健康，特别是婴儿、儿童等弱势群体的健康。 最近的冠状病毒大流行彻底震撼了世界。 清醒地提醒人们在这一领域继续进行研究和开发的重要性。 通过将世界领导人和关键意见持有者聚集在一起，RespiDART 2022 将应对药物领域的挑战 呼吸道病毒的发现/开发和疫苗的具体目标是： 1. 提供一种疫苗。 互动研讨会环境，追随者、科学家和医护人员可以分享和讨论 针对呼吸道病毒的疗法开发领域的最新医学和科学进展； 2. 制定跨学科计划，促进科学知识的中立和平衡交流 生物学、化学、药理学、临床研究和公共卫生领域的知识 主题包括流行病学和治疗障碍、疫苗开发以及最新的临床进展 小分子；3.加强对年轻科学家的培训，并为他们提供更多的机会 通过 CME 认可的参加者奖学金来减少代表性不足的科学家和卫生保健工作者 教育目标是： 1. 呼吸道病毒的流行病学、筛查和诊断。 特别关注 SARS-CoV-2 2. 药物发现和开发 3. 新型药物的临床评价。 正在开发针对呼吸道病毒（例如 SARS-CoV-2、RSV）的疗法。 副流感病毒和偏肺病毒。 5. 呼吸道病毒酶学，宿主病毒。 相互作用和病毒复制。 6. 免疫学和疫苗开发。 7. SARS-CoV-2 变体的影响。 治疗方法、疫苗和流行病学的出现。 8. 新型检测方法和动物模型开发。 10. SARS-CoV-2 和其他病毒感染和耐药性、疫苗耐药性和病毒进化。 成人和儿童群体的呼吸道疾病，包括 SARS-CoV-2/病毒合并感染。 方法：RespiDART 2022 将在墨西哥洛斯卡沃斯举行，为期两天，地点为 墨西哥国内和国际代表（包括为医疗服务的人员）可以轻松访问。 当地居民）以及来自不发达国家的众多科学家将被邀请参加。 计划将包括讲座、口头摘要演示、讨论小组和虚拟海报会议。 如果持续的大流行导致前往会议不安全，我们将设置参与选项。 我们相信 RespiDART 2022 是一个非常需要且及时的平台，用于讨论最新的 全球卫生这一快速发展领域的发展。